COMPANY

Shift Pharmaceuticals Holdings, Inc.

Location: Columbia, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $37K (STTR Phase I 5R41EY036319-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R41EY036319-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R41EY036319-02
  Organization: SHIFT PHARMACEUTICALS HOLDINGS, INC.; City/State: COLUMBIA, MO; Project number: 5R41EY036319-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 37074; Administering IC: National Eye Institute; Project title: Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — STTR: $37,074 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NEI. Source: government award database. source ↗
Aug 1, 2025 Grant Government grant — STTR: $312,239 (annual award, as published), announced Aug 1, 2025. Agency: NIH/NEI. Source: government award database. source ↗

Last 2 years.

Sep 17, 2026 Government grant — STTR: $37,074 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NEI. Source: government award database. source ↗
Aug 1, 2025 Government grant — STTR: $312,239 (annual award, as published), announced Aug 1, 2025. Agency: NIH/NEI. Source: government award database. source ↗